Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 7

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 7
---
.

Sales of LIVTENCITY (for post-transplant cytomegalovirus (“CMV”) infection/disease) were JPY 24.5 billion (JPY +10.5 billion and +75.5% AER, +66.3% CER). The increase was primarily attributable to continued U.S. performance reflecting strong market penetration, complemented by continued geographical expansion in Europe and the Growth and Emerging Markets.

Sales of enzyme replacement therapy REPLAGAL (for Fabry disease) were JPY 60.2 billion (JPY +5.2 billion and +9.4% AER, +4.6% CER). The increase was due to favorable foreign exchange rates, and increased demand in the Growth and Emerging Markets.

#### PDT
In PDT, revenue was JPY 784.2 billion (JPY +109.7 billion and +16.3% AER, +9.8% CER).

Aggregate sales of immunoglobulin products were JPY 576.0 billion (JPY +90.3 billion and +18.6% AER, +11.9% CER). Sales of each of our three global immunoglobulin brands experienced double digit percentage sales growth, due to continued strong demand globally and growing supply, as well as favorable foreign exchange rates. Those include GAMMAGARD LIQUID/KIOVIG (for the treatment of primary immunodeficiency (“PID”) and multifocal motor neuropathy (“MMN”)), and subcutaneous immunoglobulin therapies (CUVITRU and HYQVIA), sales of which are growing at a fast pace due to their benefit to patients and convenience in administration compared to intravenous therapies.

Aggregate sales of albumin products including HUMAN ALBUMIN and FLEXBUMIN (both primarily used for hypovolemia and hypoalbuminemia) were JPY 101.3 billion (JPY +7.0 billion and +7.4% AER, +2.2% CER). The increase was primarily driven by favorable foreign exchange rates.

#### Oncology
In Oncology, revenue was JPY 428.4 billion (JPY +82.1 billion and +23.7% AER, +18.7% CER).

Sales of FRUZAQLA (for colorectal cancer) were JPY 36.1 billion (JPY +33.8 billion and +1,512.9% AER, +